2013
DOI: 10.5858/arpa.2013-0002-oa
|View full text |Cite
|
Sign up to set email alerts
|

A Multiplex Technology Platform for the Rapid Analysis of Clinically Actionable Genetic Alterations and Validation for BRAF p.V600E Detection in 1549 Cytologic and Histologic Specimens

Abstract: The multiplex assay system is a sensitive and reliable method to detect BRAF c.1799T>A mutation in colorectal and thyroid lesions. This optimized technology platform is suitable for the rapid analysis of clinically actionable genetic alterations in cytologic and histologic specimens.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2014
2014
2015
2015

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 28 publications
1
6
0
Order By: Relevance
“…However, response effects for single EGFR inhibitor remain relatively modest unless the EGFR-targeted therapy is combined with other chemotherapeutics [30], [31],[32],[33]. Consistent with previous findings, we found that EGFR inhibitor gefitinib alone modestly decreased the cell viability in SW1116 and PC-9 colon cancer cell lines carrying wild-type EGFR gene [27], [28]. DNA methyltransferase inhibitors as promising anti-tumor agents have been shown to demethylate and upregulate the expression of tumor suppressor genes and display strong anti-tumor growth effect in vitro , in vivo and in the clinic [34].…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…However, response effects for single EGFR inhibitor remain relatively modest unless the EGFR-targeted therapy is combined with other chemotherapeutics [30], [31],[32],[33]. Consistent with previous findings, we found that EGFR inhibitor gefitinib alone modestly decreased the cell viability in SW1116 and PC-9 colon cancer cell lines carrying wild-type EGFR gene [27], [28]. DNA methyltransferase inhibitors as promising anti-tumor agents have been shown to demethylate and upregulate the expression of tumor suppressor genes and display strong anti-tumor growth effect in vitro , in vivo and in the clinic [34].…”
Section: Discussionsupporting
confidence: 91%
“…To determine the effects of the combination treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on human colon tumor cell viability, SW1116 [27] and LOVO cells [28] carrying wild-type EGFR gene were exposed to different concentrations of decitabine or gefitinib alone or in combination for up to 48 h, followed by the determination of cell viability using MTT assay. As shown in Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Total nucleic acid (TNA) was extracted from RNARetain-preserved FNAs using a proprietary laboratory-validated method and quantified using a NanoDrop ND1000 (NanoDrop Technologies, Waltham, MA). DNA-and RNA-based tests were performed using 20 or 40 ng of purified TNA, a single qualitative multiplex assay system based on the Signature technology platform (17)(18)(19) and reagents developed, manufactured, qualified, and released under controlled processes by Asuragen Inc., Austin, Texas. To generate qualitative positive or negative test results, assay outputs (median fluorescence intensity signals) were interpreted relative to target-specific, predetermined, laboratory-validated qualitative cutoff values corresponding to an analytical sensitivity of 0.5% to 2.5%.…”
Section: Molecular Testingmentioning
confidence: 99%
“…The reference diagnosis was established using local pathology expertise while molecular testing was performed using standardized molecular methods at a centralized clinical laboratory (17)(18)(19). All cytologic, molecular, and histologic results were collected and analyzed, including aspirates with nondiagnostic cytopathology.…”
Section: Introductionmentioning
confidence: 99%
“…The remaining samples either had no detectable QFI (n = 26) or a QFI that was measurable below 3% (n = 28). These samples were sequenced using the 1052-amplicon panel and results were compared to those obtained using a liquid bead-based assay (Signature® KRAS; Asuragen, Inc.) with a validated analytical sensitivity of 1% [46] (see Figure 6). The comparison focused on call concordance at 15 sites across the BRAF , HRAS , KRAS and NRAS genes, corresponding to the most common mutations in thyroid cancer.
Figure 6 Interplatform variant dection concordance stratified by QFI.
…”
Section: Resultsmentioning
confidence: 99%